Statin use and bone mineral density in renal transplant recipients [2]

American Journal of Transplantation

Volumn 3, Issue 10, 2003, Pages 1320-1321

  Prasad, G V Ramesh ^a   Chiu, Rick ^a   Nash, Michelle M ^a   Zaltzman, Jeffrey S ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCIUM; CYCLOSPORIN; ORAL CONTRACEPTIVE AGENT; STATINE DERIVATIVE; STEROID; VITAMIN D;

ADULT; APOPTOSIS; BONE DENSITY; BONE MINERAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE ASSOCIATION; DRUG INDICATION; DRUG MECHANISM; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; LETTER; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOCLAST; RISK BENEFIT ANALYSIS;

ADULT; BONE DENSITY; BONE DISEASES, METABOLIC; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS;

EID: 0141557824     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6143.2003.00209.x     Document Type: Letter

References (5)

1. Funkhouser HL, Adera T, Adler RA. Effect of HMG-CoA reductase inhibitors (statins) on bone mineral density. J Clin Densitom 2002; 5: 151-158.
2. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000; 355: 2218-2219.
3. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-3210.
4. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents on the skeleton. J Bone Min Res 1996; 11: 1-7.
5. Mundy G, Garrett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-1949.